A Study to Investigate the Role of Noncoding RNA miR146 Alpha as a Potential Biomarker in Prostate Cancer

• Myla Worthington

  Department of Natural Sciences, Elizabeth City State University, University of North Carolina, NC 27909, USA

• Chelsey Aurelus

  Department of Natural Sciences, Elizabeth City State University, University of North Carolina, NC 27909, USA

• Narendra Banerjee

  Department of Natural Sciences, Elizabeth City State University, University of North Carolina, NC 27909, USA

• Christopher Krauss

  Department of Natural Sciences, Elizabeth City State University, University of North Carolina, NC 27909, USA

• William Kahan

  Department of Natural Sciences, Elizabeth City State University, University of North Carolina, NC 27909, USA

• Satyendra Banerjee

  Department of Natural Sciences, Elizabeth City State University, University of North Carolina, NC 27909, USA

• Sherita Gavin

  Department of Natural Sciences, Elizabeth City State University, University of North Carolina, NC 27909, USA

• Victoria Bartlett

  Department of Natural Sciences, Elizabeth City State University, University of North Carolina, NC 27909, USA

• Gloria Payne

  Department of Natural Sciences, Elizabeth City State University, University of North Carolina, NC 27909, USA

• Jeffrey Rousch

  Department of Natural Sciences, Elizabeth City State University, University of North Carolina, NC 27909, USA

• Mukesh Verma

  Division of Cancer Control and Population Sciences, National Cancer Institute, National Institutes of Health, Suite 4E102, 9609 Medical Center Drive, Bethesda, USA

• Fazlul Sarkar

  Department of Pathology, Wayne State University and Barbara Karmanos Cancer Center, Detroit, USA

• Hirendra Nath Banerjee

  Department of Natural Sciences, Elizabeth City State University, University of North Carolina, NC 27909, USA

There is a need for additional biomarkers for the diagnosis and prognosis of prostate cancer. MicroRNAs are a class of non-protein coding RNA molecules that are frequently dysregulated in different cancers including prostate cancer and show promise as diagnostic biomarkers and targets for therapy. Here we describe the role of micro RNA 146 a (miR-146a) which may serve as a diagnostic marker for prostate cancer, as indicated from the data presented in this report. Also, a pilot study indicated differential expression of miR-146a in prostate cancer cell lines and tissues from different racial groups. This report provides a novel insight into understanding the prostate carcinogenesis.

Chiam K, Ricciardelli C, Bianco-Miotto T. Epigenetic biomarkers in prostate cancer: Current and future uses. Cancer Letters 2014; 342(2): 248-56. https://doi.org/10.1016/j.canlet.2012.02.011

Verma M. Genome-wide association studies and epigenome-wide association studies go together in cancer control. Future Oncol 2016; 12(13): 1645-64. https://doi.org/10.2217/fon-2015-0035

Blute ML, Damaschke NA, Jarrard DF. The epigenetics of prostate cancer diagnosis and prognosis: update on clinical applications. Curr Opin Urol 2015; 25(1): 83-8. https://doi.org/10.1097/MOU.0000000000000132

Brothman AR, Swanson G, Maxwell TM, et al. Global hypomethylation is common in prostate cancer cells: a quantitative predictor for clinical outcome? Cancer Genet Cytogenet 2005; 156(1): 31-6. https://doi.org/10.1016/j.cancergencyto.2004.04.004

Mishra A, Verma M. Epigenetics of solid cancer stem cells. Methods Mol Biol 2012; 86: 315-31. https://doi.org/10.1007/978-1-61779-612-8_2

Sethi S, Kong D, Land S, et al. Comprehensive molecular oncogenomic profiling and miRNA analysis of prostate cancer. Am J Transl Res 2013; 5(2): 200-11.

Severi G, Southey MC, English DR, et al. Epigenome-wide methylation in DNA from peripheral blood as a marker of risk for breast cancer. Breast Cancer Res Treat 2014; 148(3): 665-73. https://doi.org/10.1007/s10549-014-3209-y

Shen J, LeFave C, Sirosh I, et al. Integrative epigenomic and genomic filtering for methylation markers in hepatocellular carcinomas. BMC Med Genomics 2015; 8: 28. https://doi.org/10.1186/s12920-015-0105-1

Smolle M, Uranitsch S, Gerger A, et al. Current status of long noncoding RNAs in human cancer with specific focus on colorectal cancer. Int J Mol Sci 2014; 15(8): 13993-4013. https://doi.org/10.3390/ijms150813993

Czajka AA, Wojcicka A, Kubiak A, et al. Family of microRNA146 Regulates RARbeta in Papillary Thyroid Carcinoma. PLoS One 2016; 11(3): e0151968. https://doi.org/10.1371/journal.pone.0151968

Li H, Xie S, Liu M, et al. The clinical significance of downregulation of mir-124-3p, mir-146a-5p, mir-155-5p and mir-335-5p in gastric cancer tumorigenesis. Int J Oncol 2014; 45(1): 197-208. https://doi.org/10.3892/ijo.2014.2415

Koppers-Lalic D, Hackenberg M, de Menezes R, et al. Bijnsdorp, Noninvasive prostate cancer detection by measuring miRNA variants (isomiRs) in urine extracellular vesicles. Oncotarget 2016; 7(16): 22566-78. https://doi.org/10.18632/oncotarget.8124

Kristensen H, Thomsen AR, Haldrup C, et al. Novel diagnostic and prognostic classifiers for prostate cancer identified by genomewide microRNA profiling. Oncotarget 2016; 7(21): 30760-71. https://doi.org/10.18632/oncotarget.8953

Crea F, Venalainen E, Ci X, et al. The role of epigenetics and long noncoding RNA MIAT in neuroendocrine prostate cancer. Epigenomics 2016; 8(5): 721-31. https://doi.org/10.2217/epi.16.6

Costa-Silva B, Aiello NM, Ocean AJ, et al. Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver. Nat Cell Biol 2015; 17(6): 816-26. https://doi.org/10.1038/ncb3169

Ye Y, Li SL, Ma YY, et al. Exosomal miR-141-3p regulates osteoblast activity to promote the osteoblastic metastasis of prostate cancer. Oncotarget 2017; 8(55): 94834-94849. https://doi.org/10.18632/oncotarget.22014

Wotschofsky Z, Gummlich L, Liep J, et al. Integrated microRNA and mRNA Signature Associated with the Transition from the Locally Confined to the Metastasized Clear Cell Renal Cell Carcinoma Exemplified by miR-146-5p. PLoS One 2016; 11(2): e0148746. https://doi.org/10.1371/journal.pone.0148746

Li Z, Ma YY, Wang J, et al. Exosomal microRNA-141 is upregulated in the serum of prostate cancer patients. Onco Targets Ther 2016; 9: 139-48. https://doi.org/10.2147/OTT.S95565

• PDF

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.